Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge49
Pathophysiology of musculoskeletal pain: a narrative review40
Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways32
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review31
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of30
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders29
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis29
Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation25
Body composition in patients with rheumatoid arthritis: a narrative literature review24
A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening24
Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis23
A broad look into the future of rheumatoid arthritis18
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?18
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus18
Comparative effectiveness of treatment options for subacromial shoulder conditions: a systematic review and network meta-analysis18
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders18
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis17
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents17
Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review17
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)17
0.02833104133606